Paper20220189
Toward a personalized treatment of Hodgkin's disease.
DeVita VT and 1 other. N Engl J Med, 2010. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Toward a personalized treatment of Hodgkin's disease. Papers, record 20220189. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20220189
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, CD | Major topic |
| Antigens, Differentiation, Myelomonocytic | Major topic |
| Hodgkin Disease | Major topic |
| Macrophages | Major topic |
| Disease-Free Survival | |
| Gene Expression Profiling | |
| Humans | |
| Prognosis | |
| Reed-Sternberg Cells | |
| CD68 Molecule |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 20220182 | Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. | https://conductscience.org/library/papers/20220182 |
Source PubMed
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36147921 | CD20 expression is closely associated with Epstein-Barr virus infection and an inferior survival in nodular sclerosis classical Hodgkin lymphoma. | Front Oncol | 2022 | https://conductscience.org/library/papers/36147921 | PubMed |
| 32372254 | Clinico-pathological significance of immunohistochemically marked tumor-associated macrophage in classic Hodgkin lymphoma. | J Egypt Natl Canc Inst | 2020 | https://conductscience.org/library/papers/32372254 | PubMed |
| 29967610 | Hodgkin Lymphoma-Derived Extracellular Vesicles Change the Secretome of Fibroblasts Toward a CAF Phenotype. | Front Immunol | 2018 | https://conductscience.org/library/papers/29967610 | PubMed |
| 27456130 | Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern. | Am J Pathol | 2016 | https://conductscience.org/library/papers/27456130 | PubMed |
| 25916750 | Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression. | Int J Exp Pathol | 2015 | https://conductscience.org/library/papers/25916750 | PubMed |
| 21602260 | Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. | Ann Oncol | 2012 | https://conductscience.org/library/papers/21602260 | PubMed |
| 21542892 | Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. | Genome Med | 2011 | https://conductscience.org/library/papers/21542892 | PubMed |
| 21318045 | Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies. | Adv Hematol | 2011 | https://conductscience.org/library/papers/21318045 | PubMed |
| 20517336 | Hematology. Are macrophages the bad guys in Hodgkin lymphoma? | Nat Rev Clin Oncol | 2010 | https://conductscience.org/library/papers/20517336 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20220189
GET https://conductscience.org/api/papers/v1/20220189/authors